We make diagnostics that matter
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe, it’s free!
  • Search
  • Menu Menu
Clinical Laboratory int.

Archive for category: Product News

Product News

AMSBIO has expanded its range of cfPure Cell Free DNA Purification Kits

, 26 August 2020/in Product News /by 3wmedia

AMSBIO has expanded its range of cfPure™ Cell Free DNA Purification Kits for rapid and efficient isolation of circulating cell free DNA (cfDNA). A new cfPureMax kit is now available for use on samples of 5 ml volume or greater.
AMSBIO cfPure kits use silica-coated paramagnetic particles to purify cell free DNA from less than 1 ml to greater than 10 ml of serum or plasma. The buffers were developed to ensure efficient recovery of 100-500 bp DNA fragments in order to maximize recovery of cell free DNA. The recovered DNA is suitable for a wide range of down-stream applications, such as bisulfite sequencing, NGS, and qPCR.
The cfPure protocol is rapid and easy, allowing users to process several samples in an hour or less and making it ideal for biomarker screening. Using proprietary silica-coated magnetic bead technology, cfPure kits are able to efficiently recover low molecular weight cell free DNA during isolation – a key success factor for successful analysis of cfDNA. Designed for scalability, cfPure kits enable you to use just the number of beads and amount of reagent that you need for your cfDNA extraction. This also means that the number of extractions per kit is dependent on the amount of sample you wish to purify DNA from.
In addition to being easy to perform, scalable and easy to automate, cfPure kits allow you to use less magnetic bead solution if you are purifying small amounts of plasma – saving you money.
Since cfDNA is typically found at very low concentrations and in a fragmented state, very efficient DNA capture, as provided by AMSBIO’s cfPure Cell Free DNA Purification Kits, is vital to provide sensitive and reliable results.
For more information, visit www.amsbio.com/circulating-cell-free-DNA.aspx
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/NEWS_CLI_AMSBIO.jpg 532 692 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:16:522021-01-08 11:20:40AMSBIO has expanded its range of cfPure Cell Free DNA Purification Kits

SP Scienceware launches ProCulture product line for cell culture

, 26 August 2020/in Product News /by 3wmedia

SP Scienceware has introduced ProCulture, a new workflow-minded product line for cell culture from Bel-Art and Wilmad-LabGlass brands, which covers multiple steps of the cell culture process from isolation to harvesting. Products include an array of Shaker Flasks, Spinner Flasks with a unique impeller that increases aeration and eliminates dead spots, and an Orbital Shaker Platform that converts an existing magnetic stir plate into an orbital shaker at a fraction of the cost of an orbital shaker.
Kathleen Hanek, Portfolio Manager for SP Scienceware, said: “The ProCulture line includes products that can simplify researchers’ cell culture experiments. It includes tried and true items such as shaker flasks and storage racks as well as products you can’t find anywhere else.”
A catalogue of products is available here
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/scienceware_ProCulture.png 1800 1800 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:16:522021-01-08 11:20:34SP Scienceware launches ProCulture product line for cell culture

Chemiluminescence assays for the RA Analyzer 10

, 26 August 2020/in Product News /by 3wmedia

New CE-marked chemiluminescence immunoassays (ChLIA) for detection of antibodies against Borrelia, Epstein-Barr virus (EBV-CA, EBNA), proteinase 3 (PR3) and phospholipase A2 receptor (PLA2R) on the EUROIMMUN RA Analyzer 10 system are available now. Different immunoglobulin classes can be analysed depending on the application, with assays encompassing anti-Borrelia IgG and IgM, anti-EBV-CA IgG and IgM, anti-EBNA IgG, anti-PR3 IgG and anti-PLA2R IgG. The random access system, used in conjunction with the ChLIA products, functions as a compact automation solution in small- to medium-sized laboratories, or complements high-throughput-devices in large-sized laboratories. Test- and lot-specific information, including stored standard curves, are imported into the database by means of an RFID code, enabling error-free and convenient loading, along with efficient and secure test evaluation. The EURO-IMMUN RA Analyzer 10 allows continuous loading — also as part of a laboratory track system — to ensure that every sample is processed with minimal effort as a single determination. The ChLIA technology offers short reaction times, with total analysis in 30 minutes or less. In addition, the preferred processing of emergency samples (STAT) gives laboratories with different requirements and sample volumes flexibility in their laboratory routine.
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/EUROIMMUN_CLI_OCT_2019_RA_Analyzer.jpg 534 800 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:16:522021-01-08 11:20:45Chemiluminescence assays for the RA Analyzer 10

D-Dimer reagent for Yumizen G hemostasis range

, 26 August 2020/in Product News /by 3wmedia

Now available for Horiba Medical’s Yumizen G hemostasis range of instruments, the new Yumizen G DDi 2 (D-Dimer) reagent kit offers a key measurement and reference exclusion test for the diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It can also be used for monitoring the progress and effectiveness of treatment of Disseminated Intravascular Coagulation (DIC). HORIBA Medical’s new D-Dimer reagent kit is available for its full range of coagulation instruments which covers the needs of any laboratory. The dedicated hemostasis portfolio includes the fully automatic Yumizen G800, Yumizen G1500 and Yumizen G1550, as well as semi-automatic Yumizen G200 and Yumizen G400 analysers. Using antibody-coated latex particles and measured via the immuno-turbidimetric channels of these Yumizen G instruments, the new reagent kit delivers D-Dimer results consistency across the range.  The D-Dimer assay when used on very compact coagulation screening platforms such as the Yumizen G400DDi and Yumizen G200, which also have combined immuno-turbidimetric and chromogenic assay capabilities, is particularly suitable for small laboratories, hot labs and as backup. On these semi-automatic systems, the Yumizen G DDi 2 reagent kit offers an innovative combination of immuno-turbidimetric test capability and pre-calibrated ready-to-use reagent. Offering a cost-efficient solution, the new assay minimizes preparation time due to its ready-to-use liquid format. Furthermore, as the reagent is pre-calibrated it removes the need for a costly and time-consuming calibration step. Its high stability and optimized volume packaging also avoid wastage. HORIBA Medical’s new D-Dimer test kit is fully compliant with Gold Standard performances, having a Negative Predictive Value of 99% and an absence of hook effect up to 25 µg FEU/ml. It also offers slope check and post dilution function on both fully automatic and semi-automatic systems with a cut-off value at 0.5 µg FEU/ml.

HORIBA MEDICAL
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/C430_Horiba_Yumizen_G200_coagulation_analyser.jpg 709 800 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:16:522021-01-08 11:20:53D-Dimer reagent for Yumizen G hemostasis range

Characterising virus & virus-like particles

, 26 August 2020/in Product News /by 3wmedia

Postnova Analytics reports how its latest generation of Asymmetrical Flow Field Flow Fractionation (AF4) systems are providing labs worldwide with a uniquely powerful technique to characterize and quantitate virus and virus-like particles.
Virus and virus-like particles are widely used in the healthcare industry for vaccination via immune response stimulation. Because these particles are to be injected into patients there is a critical requirement for a technique that allows detection and separation of the monomeric, oligomeric and aggregated species in a typical formulation.
While Size Exclusion Chromatography (SEC) has been a traditional analytical technique used for this application it has significant limitations relating to the size exclusion limit of the separation column that restricts the upper molar mass and particle size range that can be measured.
By comparison, Asymmetrical Flow Field Flow Fractionation (AF4) is an advanced separation technique that can address the problems associated with SEC. In AF4, an open, unpacked separation channel is used in place of a packed column. The absence of a stationary phase in AF4 systems results in the ability to use a wider range of solvents, elimination of SEC shear force and matrix interaction effects as well as the ability to separate particles over a very wide size range, from 1 nm up to above 1 µm. These capabilities enable AF4 to provide a complete picture of virus and virus-like particles including monomer content, insoluble and soluble aggregates, as well as the subvisible particle fraction.

  • For a copy of a new application study describing the separation and characterisation of adeno associated virus serotypes by AF4, visit https://bit.ly/2SXdyPj
  • To discuss how AF4 systems can separate and characterise your virus, virus-like particles and vaccine components please email Postnova Analytics: info@postnova.com

Founded in 1997, Postnova Analytics is the inventor and leading international supplier of Field-Flow Fractionation (FFF) systems for markets including biopharmaceuticals, polymers, materials, nanotechnology and environmental sciences.
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/postnova.png 1000 1000 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:16:522021-01-08 11:20:29Characterising virus & virus-like particles

Multiplex assay for 10 STI’s receives CE mark

, 26 August 2020/in Product News /by 3wmedia

CE marking has been granted to one of the most comprehensive cartridge-based STI tests. The test, developed by the UK’s largest health diagnostics company, Randox Laboratories, tests simultaneously for 10 of the most common sexually transmitted infections, on the firm’s patented Biochip Technology. Quickly and efficiently testing for multiple STIs, which often have mild symptoms if any at all, ensures early diagnosis at a stage when treatment is most successful, supports the targeted use of antibiotics, and ultimately reduces their mishandling. Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented; “Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. The CE marking of the STI assay, which incorporates Randox Biochip Technology, will be a game-changer for clinicians and patients across Europe, by facilitating early, accurate and comprehensive diagnoses of STIs that allows for the best possible patient outcome. Never before has there been this level of accessibility and speed with regards to STI testing.”
The Randox STI assay is performed on the Vivalytic system, an intuitive point-of-care platform, developed in partnership with German technology company Bosch that provides the broadest range of test options ever seen for an analyser of its size. Harnessing the application of multiplex assays to provide greater information from a single patient sample, the Vivalytic simplifies the testing process for otherwise complex laboratory testing procedures.
Marc Meier, Managing Director of Bosch Healthcare Solutions, a subsidiary of Bosch Group, said: “We are enthusiastic about partnering with Randox to offer their assay technology on the Vivalytic platform. The core competencies of Bosch in automation, miniaturization, sensor technology and connectivity are complemented by Randox’s expertise in developing excellent biocontent for a wide range of assays and commercializing innovative diagnostic solutions.”
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/PRODUCT_CLI_BOSCH.jpg 467 768 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:16:522021-01-08 11:20:37Multiplex assay for 10 STI’s receives CE mark

Drugs of Abuse Testing in Urine by LC-MS/MS

, 26 August 2020/in Product News /by 3wmedia

The LC-MS/MS-based assay MassTox drugs of abuse testing offers the target screening and quantitative confirmation of more than 100 drugs and metabolites with an analysis time of up to 12 minutes. The CE-IVD validated solution includes everything that is required for the analysis, eliminating the need for developing and maintaining several in-house methods or for preparing QC materials for a multitude of analyte compounds. It is designed to work below cut-offs defined by GTFCh and EWDTS. The assay includes a carefully selected hydrolysis enzyme that ensures a complete and selective hydrolysis of all 108 drugs covered in the assay. 99 analytes are safeguarded by isotopically labelled internal standards. The high stability of the 6PLUS1 Multilevel Urine Calibrator Set and three MassCheck urine controls ensure reliable results with highest precision.

Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/C346_ChromSystems__New_Assay_Drugs_of_Abuse_Chromsystems.jpg 581 800 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:16:522021-01-08 11:33:30Drugs of Abuse Testing in Urine by LC-MS/MS

Thermo Fisher Scientific introduces new mass spectrometry systems

, 26 August 2020/in Product News /by 3wmedia

Thermo Fisher Scientific has introduced several new products that build on its leading Orbitrap platform and expand research applications. The new Thermo Scientific Orbitrap Exploris 240 mass spectrometer is designed to give scientists working in proteomics, metabolomics, biopharmaceutical characterisation and small-molecules, the analytical performance required for research and high-throughput analyses. The company says the new system will advance discovery and identification with increased accuracy for confident scale-up, while providing operational simplicity and streamlining time-to-result.
Thermo Fisher Scientific pointed out that the new mass spectrometer delivers qualitative and quantitative capabilities synonymous with Orbitrap high-resolution accurate-mass (HRAM) spectrometry, with internal calibration that assures consistent data quality and decision making. These newest systems extend the Thermo Scientific Orbitrap Exploris portfolio of HRAM systems, which were introduced in 2019 with the release of the new-generation Thermo Scientific Orbitrap Exploris 480 mass spectrometer.
Software
Thermo Scientific Proteome Discoverer 2.5 software provides high confidence during peptide identification, accurate quantification and high throughput data analysis for proteomics researchers. Deep learning-based prediction of tandem mass spectra, facilitated through a new collaboration with MSAID, a software company transforming proteomics through deep learning, enables more scientists to benefit from major improvements in identification confidence and reproducibility.
To further enhance characterisation of protein biotherapeutics and oligonucleotide therapeutics, biopharmaceutical laboratories use the Thermo Scientific BioPharma Finder 4.0 software, which provides greater flexibility and customisation for this growing industry.
For small molecule researchers, Thermo Scientific Compound Discoverer 3.2 software further automates unknown compound identification performed on Thermo Scientific Orbitrap Gas Chromatography- Mass Spectrometry (GC-MS) systems to improve productivity.
In addition, the new Thermo Scientific Xcalibur 4.4 software brings the AcquireX intelligent data acquisition workflow to Thermo Scientific Orbitrap Exploris mass spectrometry platform users, enabling the fully automated acquisition of high quality MS/MS data and reducing manual input and repeat runs.
Collaboration
Thermo Fisher Scientific’s collaboration with Evosep, a leading provider of sample preparation technologies for protein-based clinical research, supports the development of high-throughput clinical research workflows for profiling large plasma sample cohorts for proteomics, translational research and pharmaceutical applications. This partnership recently led to the launch of an automated ultra-high throughput plasma protein profiling platform, combing the power of the new Thermo Scientific Orbitrap Exploris 240 mass spectrometer with the Evosep One liquid chromatography solution.
The company’s collaboration with Biognosys, a leading developer of next-generation proteomics solutions, resulted in the development of data-independent acquisition mass spectrometrybased workflows, which enhances sensitivity and coverage for proteomic research in translational and clinical labs. The collaboration includes a novel FAIMS-DIA method that features the Thermo Scientific FAIMS Pro interface, which improves selectivity, reproducibility and proteome coverage, as well as new methods that streamline discovery by combining Thermo Scientific SureQuant Targeted Assay Kits and the Biognosys PQ500 kit in a single workflow.
For more information, visit: www.thermofisher.com
Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/AD_THERMO_FISHER.jpg 532 501 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:16:522021-01-08 11:20:32Thermo Fisher Scientific introduces new mass spectrometry systems

Total solution for lipid and cardiac risk testing

, 26 August 2020/in Product News /by 3wmedia

Cardiovascular disease caused by atherosclerosis is the leading cause of morbidity in Western Countries [1]. It involves the hardening and narrowing of vessels in the systemic system. The process originates from the build-up of fatty deposits through a process known as atherogenesis. If the build-up increases, plaque rupturing may occur leading to myocardial infarction [2].
The mission of The National Lipid Association (NLA) is “to enhance the practice of lipid management in clinical medicine.” NLA advocates advancing the current lipid testing profile as the traditional panel consists of testing LDL cholesterol (LDL-C), HDL cholesterol (HDL-C) and triglycerides, which only detects approximately 20 % of all atherosclerotic cardiovascular disease patients. Advanced lipid testing is recommended to optimize patient treatment [3].
Offering a total solution for lipid and cardiac risk testing, Randox has developed novel and superior performance markers to identify the true weight of lipid profiling. Its range of niche and superior performance assays comprises 13 assays including: small dense LDL-C (sdLDL-C), Lipoprotein (a) (Lp(a)) and HDL3-C.
sdLDL-C will more readily permeate the inner arterial wall having a lower affinity to the hepatic LDL-C receptor which circulates in the blood longer and more susceptible to oxidation.
As sdLDL-C is particularly atherogenic, a person with elevated sdLDL-C levels has a 3-fold increased risk of myocardial infarction [4].
Elevated Lp(a) levels are associated robustly and specifically with increased cardiovascular disease (CVD) risk. The unique Randox Lp(a) assay is one of the only methodologies on the market that detect the non-variable part of the Lp(a) molecule which suffers minimal size related bias.
HDL3-C is the scavenger of cholesterol within arterial walls and if HDL3-C levels are significantly depleted, the ability to remove this cholesterol is reduced. Therefore, it is widely accepted that there is an inverse correlation between HDL3-C and CVD risk.
It is necessary to review the traditional lipid testing panel, enabling clinicians to gain a more comprehensive view of a patient’s CVD risk and therefore take the appropriate
measures to prevent CVD related deaths.
References
1. Burnett JR. Lipids, lipoproteins, atherosclerosis and cardiovascular disease. Clin Biochem Rev 2004; 25(1): 2 [cited: 3 December 2018]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1853363/.
2. Zimmermaann KA. Circulatory system: facts, function & diseases. Live Science [Online] 16 March 2018 [cited: 3 December 2018]. https://www.livescience.com/22486-circulatory-system.html.
3. National Lipid Association. National Lipid Association releases updated recommendations on the use of PCSK9 inhibitors at the 15th Annual Scientific Session. [Online] no date [cited: 3 December 2018]. https://www.lipid.org/nla/national-lipid-association-releases-updated-recommendations-use-pcsk9-inhibitors-15th-annual.
4. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. LDL subclass patterns and risk of MI. JAMA 1988; 260(13): 1917–1921.

Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/Randox_Lipid_Graphic.jpg 518 800 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:16:522021-01-08 11:20:40Total solution for lipid and cardiac risk testing

Total laboratory automation solution sets new standard for turnaround time

, 26 August 2020/in Product News /by 3wmedia

Beckman Coulter announced early May that the latest addition to its automation portfolio, the DxA 5000 total laboratory automation solution, has achieved European CE Mark and China Food and Drug Administration approval. In today’s healthcare environment, laboratories are highly focused on enhancing patient care by driving faster turnaround time, delivering quality results and improving laboratory operations. The DxA 5000 helps laboratories meet these challenges through a collection of patented innovations that deliver rapid and consistent turnaround time, provide a new level of comprehensive pre-analytical sample quality detection, and reduce the number of manual processing steps to significantly improve laboratory efficiency.
Reporting results faster to physicians can positively impact patient outcomes. In the laboratory, specimen centrifugation is typically the most time-consuming pre-analytical activity. The DxA 5000 sets a new standard by utilizing a universal centrifugation protocol that significantly reduces the pre-analytical processing time by up to 73% for connected analysers across multiple disciplines.
Additionally, the DxA 5000 supports laboratories in delivering highly consistent turnaround time to their physicians. Leveraging first-of-its-kind dynamic system software, the DxA 5000 utilizes Intelligent Routing to bring automated patient-centric workflow to the laboratory. By understanding the tests requested, sample volume available and real-time analyser capacity and status, the DxA 5000 continuously calculates the most expeditious route for every patient sample – both STAT and routine.
Research shows errors that occur in the pre-analytical phase of testing may contribute up to 75% of erroneous test results, with 26% possibly having adverse effects on patient care.  Moreover, a vast majority of the factors causing erroneous results occur outside the laboratory, including inadequate volume, mislabeled samples and incorrect tube type. The DxA 5000 is designed with a sharp focus on sample quality assessment, screening each sample at multiple points to help laboratories substantially reduce the risk of errors. In three seconds, the system detects patient tube parameters such as volume, sample identification, tube type, cap colour, orders pending and tube weight. The system is also designed to check for sample volume at three separate points: pre-centrifugation, post-centrifugation and prior to sample storage to continually ensure sufficient volume is available for the tests ordered. Together, these quality assessments reduce the potential for release of erroneous results and can help accelerate time to result by quickly alerting the laboratory when a new patient sample is needed.
In addition to improving sample quality, laboratories also require workflow solutions that help them manage high volumes of outpatient, outreach and network samples, while processing urgent requests for both patient wards and emergency departments. The DxA 5000 simultaneously manages high volumes of multiple discipline requests, with a large variety of patient sample tubes and sizes, without impact to overall system throughput or STAT turnaround time. By automating sample processing steps, the DxA 5000 supports laboratories in delivering a higher number of results per hour with the same staffing level.
Based on research and work performed with the company’s laboratory partners, sample processing steps are shown to make up approximately 70% of a laboratory’s labour hours. The DxA 5000 significantly reduces the number of manual steps in sample processing to as few as one. From sample accessioning and quality assessment to add-on test management and sample disposal, the DxA 5000 enables laboratory professionals to deliver high-quality results and improve efficiency, empowering them to focus their efforts and skills on managing patient sample exceptions.
The first in a suite of DxA systems currently in development, the DxA 5000 enhances Beckman Coulter’s comprehensive portfolio of scalable solutions and is a key component of its vision to bring workflow automation to laboratories of all sizes.
Beckman Coulter has received purchase orders for more than 20 DxA 5000 systems across multiple countries where regulatory clearance has been achieved.

Read more

https://clinlabint.com/wp-content/uploads/sites/2/2020/08/C436_BECKMAN_DxA_5000_NEW_IMAGE.jpg 613 800 3wmedia https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png 3wmedia2020-08-26 09:16:522021-01-08 11:20:50Total laboratory automation solution sets new standard for turnaround time
Page 114 of 115«‹112113114115›
Forum Labo Paris March 2023

Latest issue of Clinical laboratory

February 2023 / March 2023

24 March 2023

Soluble Transferrin Receptor (sTfR) assays for IMMAGE®, ADVIA® and other Clinical Chemistry analyzers

24 March 2023

Total bile acids 21 FS

24 March 2023

Integrative solutions at the speed of life

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release

Hastelweg 250
5652 CN Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com

PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only